Recovering abandoned compounds through expanded external IP licensing

California Management Review

Volumn 55, Issue 4, 2013, Pages 83-101

  Chesbrough, Henry ^a   Chen, Eric L ^b  

^a University of California at Berkeley   (United States)

^b ONYX PHARMACEUTICALS   (United States)

Author keywords

Abandoned compounds; Biotechnology; Business models; Innovation management; Intellectual property; IP management; Licensing; Open innovation; Out licensing; Pharmaceuticals; R D; R D productivity

Indexed keywords

EID: 84925326363     PISSN: 00081256     EISSN: 21628564     Source Type: Journal    
DOI: 10.1525/cmr.2013.55.4.83     Document Type: Article

References (43)

1. J. Hunter, "Is Open Innovation the Way Forward for Big Pharma?" Nature Reviews Drug Discovery, 9(February 2010):87-88.
2. J. A. DiMasi, L. Feldman, A. Seckler, and A. Wilson, "Trends in Risks Associated with New Drug Development: Success Rates for Investigational Drugs", Clinical Pharmacology & Therapeutics, 87/3(March 2010):272-277.
3. H. Chesbrough, Open Business Models: How to Thrive in the New Innovation Landscape (Boston, MA: Harvard Business School Press, 2006), pp. 32 and 33.
4. H. Chesbrough and E. L. Chen, "The Recovery of Abandoned Compounds: A Rationale for Stimulating Secondary Markets in Pharmaceutical Drug Development", working paper, Haas School of Business, UC Berkeley, 2012.
5. G. Pisano, Science Business: The Promise, the Reality, and the Future of Biotech (Boston, MA: Harvard Business School Press, 2006a).
6. H. Chesbrough, Open Innovation: The New Imperative for Creating and Profiting from Technology (Boston, MA: Harvard Business School Press, 2003).
7. R. M. Cyert and J. G. March, A Behavioral Theory of the Firm (Englewood Cliffs, NJ: Prentice Hall, 1963).
8. Chesbrough (2003), op. cit., Chapter 4.
9. G. Annas and S. Elias, "Thalidomide and the Titanic: Reconstructing the Technology Tragedies of the Twentieth Century", Health Law and Ethics, 89/1(January 1999):98-101.
10. J. Blake Bartlett, K. Dredge, and A. G. Dalgleish, "The Evolution of Thalidomide and Its IMiD Derivatives as Anticancer Agents", Nature Reviews Cancer, 4(April 2004):314-322.
11. H. DeMonaco, A. Ayfer, and E. Von Hippel, "The Major Role of Clinicians in the Discovery of Off-Label Drug Therapies", Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 26/3(2006):323-332.
12. J. A. DiMasi, "Risks in New Drug Development: Approval Success Rates for Investigational Drugs", Clinical Pharmacology & Therapeutics, 69/5(May 2001):297-307.
13. B. I. Eisenstein, F. B. Oleson, Jr., and R. H. Baltz, "Daptomycin: From the Mountain to the Clinic, with Essential Help from Francis Tally, MD", Clinical Infectious Diseases, 50 (January 2010):S10-S15.
14. F. Tally and M. DeBruin, "Development of Daptomycin for Gram-Positive Infections", Journal of Antimicrobial Chemotherapy, 46/4(2000):523-526.
15. Cubist 2011 annual report.
16. Each interview was conducted with a semi-structured instrument of questions regarding the respondent's experience with the management of IP for abandoned or unused compounds. Where geographically possible, these interviews were conducted in face-to-face discussions. Where geographic distance was large, we relied on phone interviews. Each interview ranged from 30 minutes to over an hour in length. Respondents were chosen for their ability to speak to key questions based on having had direct experience with abandoned compounds in the pharmaceutical industry, either in a business development role or as a senior functional leader in their respective companies. Each participant had at least 7 years of industry experience, with an average tenure in the range of 15-20 years. We determined we had reached a sufficient sample size once marginal improvements to our story became small. K. M. Eisenhardt, "Building Theories from Case Study Research", Academy of Management Review, 14/4(October 1989):532-550. In order to further explore the IP challenges and framework, we also interviewed several patent attorneys with pharmaceutical IP expertise to supplement our understanding of IP issues in the drug development process.
17. Eisenhardt (1989), op. cit.
18. D. J. Teece, "Profiting from Technological Innovation: Implications for Integration, Collaboration, Licensing and Public Policy", Research Policy, 15/6(December 1986):285-305;
19. P. Grindley and D. Teece, "Managing Intellectual Capital: Licensing and Cross-Licensing in Semiconductors and Electronics", California Management Review, 39/2(Winter 1997):8-21;
20. G. Pisano, "Profiting from Innovation and the Intellectual Property Revolution", Research Policy, 35/8(October 2006b):1122-1130.
21. G. Akerlof, "The Market for 'Lemons': Quality Uncertainty and the Market Mechanism", The Quarterly Journal of Economics, 84/3(1970):488-500.
22. R. Katz and T. J. Allen, "Investigating the Not Invented Here (NIH) Syndrome: A Look at the Performance, Tenure, and Communication Patterns of 50 R&D Project Groups", R&D Management, 12/1(January 1982):7-20.
23. Good Manufacturing Practice is a set of industry standards that regulatory agencies such as the FDA and the WHO require drug manufacturers to follow in order to ensure patient health. Advisory guidelines are promulgated by the agencies from time to time. See , accessed August 29, 2012.
24. We recognize that some of the provisions discussed in our framework may make a licensing deal less attractive from the perspective of the IP buyer. However, the focus here is on considerations for the IP seller. Therefore, our main goal in this article has been to explain out-licensing barriers and potential avenues to overcome them. Moreover, the presence of these additional considerations broadens the scope of negotiations between buyer and seller, increasing the chance that a mutually acceptable agreement might be found. In a related paper, we examine the two-sided market dimensions of rescuing abandoned compounds, and consider the buyer perspective in more detail. Chesbrough and Chen (2012), op. cit.
25. R. Katila, E. L. Chen, and H. Piezunka, "All the Right Moves: How Entrepreneurial Firms Compete Effectively", Strategic Entrepreneurship Journal, 6/2(2012):116-132.
26. Chesbrough and Chen (2012), op. cit.
27. The U. S Orphan Drug Act, signed into law in 1983, was designed to encourage the development of drugs for rare diseases (defined as those affecting fewer than 200, 000 people in the United States). Drug development for rare diseases previously had been limited due to high investment costs, limited market potential, and difficulty enrolling patients to clinical trials.
28. B. Hughes, "Rare Incentives", Nature Reviews Drug Discovery, 7(March 2008):190-191.
29. B. Berkrot and R. Pierson, "Pfizer Trims Drug Pipeline after Wyeth Merger", Reuters, January 27, 2010.
30. M. Marx, D. Strumsky, and L. Fleming, "Mobility, Skills, and the Michigan Non-Compete Experiment", Management Science, 55/6(June 2010):875-889.
31. Gideon Parchomovsky and R. Polk Wagner, 2004 "Patent Portfolios", Scholarship at Penn Law School, Paper #51, 8-22-2004.
32. K. A. Moore, "Worthless Patents", George Mason Law & Economics Research Paper, 2005, pp. 4-29.
33. Chesbrough (2006), op. cit., Chapter 8.
34. Dan'l Lewin, "Microsoft's Approach to Open Innovation", address to the Haas School of Business Open Innovation Speaker Series, UC Berkeley, March 9, 2009, .
35. E. L. Chen, R. Katila, R. McDonald, and K. M. Eisenhardt, "Life in the Fast Lane: Origins of Competitive Interaction in New vs. Established Markets", Strategic Management Journal, 31/13(December 2010):1527-1547.
36. R. Katila and E. L. Chen, "Effects of Search Timing on Innovation: The Value of Not Being in Sync with Rivals", Administrative Science Quarterly, 53/4(December 2008):593-625.
37. Chesbrough and Chen (2012), op. cit.
38. Teri Melese, Salima Lin, Julia Chang, and Neal Cohen, "Open Innovation Networks between Academia and Industry: An Imperative for Breakthrough Therapies", Nature Medicine, 15(2009):502-509;
39. Hunter (2010), op. cit.
40. L. Jarvis, "Finding New Homes for Merck's Axed Assets", Chemical & Engineering News, July 6, 2011.
41. Poly ADP-ribose polymerase (PARP) inhibitor, Rucaparib, formerly PF-01367338.
42. "AstraZeneca Deepens Collaboration with Academia", Reuters, October 30, 2012.
43. "Roche and the Broad Institute Collaborate to Find New Uses for Abandoned Compounds", The Burrill Report, November 30, 2012.